


Pharmaceuticals & Biotechnology | Mid Cap
Glenmark Pharmaceuticals demonstrates a mixed financial performance. The company shows very strong solvency and profitability, driven by effective debt management and robust returns on its capital, equity, and assets. Growth prospects are promising, particularly in revenue and operating profit, but are offset by declines in EPS and net income. Liquidity is acceptable, but there is room for improvement. Efficiency in asset utilization is a notable area of concern. Overall, while Glenmark exhibits financial strengths, addressing efficiency and select growth metrics will be crucial for sustained success. The company maintains a strong coverage ratio, indicating it can comfortably handle its interest and dividend obligations.
Glenmark Pharmaceuticals demonstrates a mixed financial performance. The company shows very strong solvency and profitability, driven by effective debt management and robust returns on its capital, equity, and assets. Growth prospects are promising, particularly in revenue and operating profit, but are offset by declines in EPS and net income. Liquidity is acceptable, but there is room for improvement. Efficiency in asset utilization is a notable area of concern. Overall, while Glenmark exhibits financial strengths, addressing efficiency and select growth metrics will be crucial for sustained success. The company maintains a strong coverage ratio, indicating it can comfortably handle its interest and dividend obligations.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
-318.82
Industry Median
30.92
Mid Cap Median
41.06
P/E RATIO
47.04
P/B RATIO
6.10
Industry Median
3.39
Mid Cap Median
7.42
P/S RATIO
3.77
Industry Median
3.36
Mid Cap Median
6.69
Others
PEG RATIO
0.00
EV/EBITDA RATIO
22.94
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹2270 as on Aug 6, 2026.
The company demonstrates mixed growth performance. While revenue and operating profit growth are strong, indicating market expansion and improved operational efficiency, EPS and net income growth are negative. This suggests that profitability is not keeping pace with revenue growth, potentially due to rising costs or other factors impacting the bottom line. The weighted average calculation emphasizes recent performance, reflecting the company's present growth trends.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 12.44 | -5.87 | 1.99 | 12.77 | 27.48 |
| Operating Profit Growth Rate | 11.66 | -29.74 | -26.91 | 96.74 | 94.47 |
| Earnings Per Share (EPS) Growth | -2.94 | -68.44 | -605.41 | -169.73 | 30.05 |
| Asset Growth Rate | 9.48 | 13.6 | -25.88 | 11.37 | 24.5 |
| Net Income Growth Rate | 2.47 | -62.07 | -480.37 | -173.01 | 30.09 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Abbott India Ltd | 8.68 | 38.14 | Neutral | 1892.00 | 730.39 | 1552.00 |
| 2 | Glaxosmithkline Pharmaceuticals Ltd | 8.38 | 42.18 | Neutral | 1309.00 | 59.73 | 1036.00 |
| 3 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 54.51 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 4 | Alkem Laboratories Ltd | 8.08 | 29.08 | Neutral | 3005.00 | 182.76 | 2351.00 |
| 5 | Gland Pharma Ltd | 7.91 | 41.83 | Overvalued | 1630.00 | 78.78 | 1027.00 |
| 6 | Neuland Laboratories Ltd | 7.84 | 75.93 | Highly Overvalued | 574.00 | 283.01 | 364.00 |
| 7 | Ajanta Pharma Ltd | 7.72 | 41.06 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 8 | Emcure Pharmaceuticals Ltd | 7.40 | 39.72 | Neutral | 1865.00 | 38.64 | 941.00 |
| 9 | Syngene International Ltd | 7.16 | 50.86 | Overvalued | 918.00 | 7.55 | 317.00 |
| 10 | Laurus Labs Ltd | 7.10 | 111.18 | Neutral | 1778.00 | 13.71 | 890.00 |
| 11 | Glenmark Pharmaceuticals Ltd | 6.36 | 47.04 | Neutral | 4572.00 | -7.12 | 1362.00 |
| 12 | Ipca Laboratories Ltd | 6.33 | 38.55 | Neutral | 1979.00 | 44.64 | 1184.00 |
| 13 | Piramal Pharma Ltd | 5.83 | -85.00 | Neutral | 922.00 | 5.26 | -326.00 |
| 14 | Pfizer Ltd | 3.45 | 48.81 | Neutral | -82.00 | 157.92 | 300.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Quarterly Report⬤30th Jan 26
Quarterly Financial Results Q3 FY 2025-26
NEUTRAL SENTIMENT